Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$14.15 USD
+0.33 (2.39%)
Updated Apr 26, 2024 04:00 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
URGN 14.15 +0.33(2.39%)
Will URGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for URGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for URGN
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
URGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates
UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why
Other News for URGN
Buy Rating Affirmed for Urogen Pharma Amid Promising Clinical Data and Strategic Conference Presentations
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
NorthStar Appoints Peter Pfreundschuh to Board of Managers
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma announces FDA acceptance of UGM-103 IND